Guerbet Announces Plans to Streamline Its Contrast Media Portfolio
July 10 2017 - 1:00AM
Villepinte
(France), July 10, 2017 (7:00 AM CET) - Guerbet (FR0000032526
GBT), the global specialist in contrast products and solutions for
medical imaging, announced today that it will phase out sales
throughout the world of two products: Hexabrix® (meglumine and
sodium ioxaglate) and Optimark® (gadoversetamide).
Following the acquisition of
Mallinckrodt's contrast media & delivery systems business,
Guerbet has taken measures to streamline its brand portfolio.
In 2015, it announced the
withdrawal in the US of Hexabrix®, an iodinated contrast medium for
X-ray imaging that has the same indications as two other Guerbet
products, Optiray® (ioversol) and Xenetix® (iobitridol). Hexabrix®
sales in Europe, Asia and Latin America will progressively cease,
by the end of 2019 at the latest. Guerbet's offer (Optiray® and
Xenetix®) covers more than 70 countries.
Similarly, Guerbet's decision to
phase out Optimark® is part of its product portfolio
prioritization. Optimark® and Dotarem® (gadoteric acid) are both
gadolinium-based contrast agents and have similar indications for
MRI. Optimark® is a linear agent and faces decreasing worldwide
demand, while Dotarem®, a macrocyclic and ionic agent, has seen
worldwide demand increase. Dotarem® is registered in more than 70
countries.
Sales of Optimark® will end first
July 26, 2017 in European Union countries. Then, and in order to
ensure a smooth transition and continuous supply for patients,
Optimark® phase out will be progressively implemented in other
geographic areas until end of 2019.
This move to streamline its
gadolinium-based contrast agent portfolio through a focus on
Dotarem® is consistent with recent recommendations of
the Pharmacovigilance Risk Assessment Committee (PRAC) of
the European Medicines Agency (see July 7th, 2017
PRAC press release here).
"This rationalization will enable
us to live up to our undertaking to offer health professionals a
complete range of efficient and safe contrast media to improve
diagnosis, prognosis and quality of life for patients all over the
world, while ensuring our enhanced industrial and commercial
efficiency", says Guerbet CEO Yves L'Epine.
About
Guerbet
Guerbet is a pioneer in the
contrast agent field with over 90 years' of experience and is one
of the leaders in medical imaging worldwide. It offers a full range
of pharmaceutical products, medical devices and services for X-ray
(RX) and Magnetic Resonance Imaging (MRI) scanners and
Interventional Radiology and Theranostics (IRT) to improve the
diagnosis and treatment of patients. With 7% of its revenue and
more than 200 employees dedicated to R&D, Guerbet invests
heavily in research and innovation. Guerbet (GBT) is listed on
Euronext Paris (Segment B - Mid Caps) and generated €776 million in
revenue in 2016. For more information about Guerbet, visit
www.guerbet.com
Guerbet
Global
Alize RP
Caroline Carmagnol & Wendy Rigal
+33 (0)1 44 54 36 66 / +33 (0)6 48 82 18 94
guerbet@alizerp.com
|
Guerbet
US
Ted Deutsch
(609) 578-8765
ted@taftcommunications.com
|
Press release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: GUERBET via Globenewswire
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024